CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 720-728

  Antonicelli, F ^a   Lorin, J ^a   Kurdykowski, S ^a   Gangloff, S C ^a   Le Naour, R ^a   Sallenave, J M ^b   Hornebeck, W ^a   Grange, F ^a   Bernard, Philippe ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM INVASIVENESS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79953688994     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10176.x     Document Type: Article

References (49)

1. Smyth MJ, Cretney E, Kershaw MH et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275-93. (Pubitemid 39576919)
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45.
3. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118:915-22. (Pubitemid 34639168)
4. Opdenakker G, van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 2004; 48:519-27. (Pubitemid 39360402)
5. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005; 93:159-87. (Pubitemid 41557275)
6. van Kempen LC, van Muijen GN, Ruiter DJ. Stromal responses in human primary melanoma of the skin. Front Biosci 2005; 10:2922-31. (Pubitemid 40910531)
7. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119:2026-9. (Pubitemid 44423657)
8. van Kempen LC, van Muijen GN, Ruiter DJ. Melanoma progression in a changing environment. Eur J Cell Biol 2007; 86:65-7. (Pubitemid 46140574)
9. Wang JM, Deng X, Gong W et al. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998; 220:1-17. (Pubitemid 28527062)
10. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18:593-620. (Pubitemid 30365392)
11. Mellado M, de Ana AM, Moreno MC et al. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol 2001; 11:691-6. (Pubitemid 32418165)
12. Richmond A, Fan GH, Dhawan P et al. How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found Symp 2004; 256:74-89.
13. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37. (Pubitemid 43053650)
14. Dhawan P, Su Y, Thu YM et al. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem 2008; 283:15399-408.
15. Lauerova L, Dusek L, Simickova M et al. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002; 49:159-66. (Pubitemid 34728793)
16. McCarter M, Clarke J, Richter D et al. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005; 138:321-8. (Pubitemid 41253817)
17. Clemente CG, Mihm MC Jr, Bufalino R et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-10. (Pubitemid 26102328)
18. Lowes MA, Bishop GA, Crotty K et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108:914-19. (Pubitemid 27272409)
19. Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993; 178:1057-65. (Pubitemid 23260444)
20. Feldman AL, Friedl J, Lans TE et al. Retroviral gene transfer of interferon- inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99:149-53. (Pubitemid 34273212)
21. Yang J, Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004; 9:846-55. (Pubitemid 38878130)
22. Mullins IM, Slingluff CL, Lee JK et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64:7697-701. (Pubitemid 39446899)
23. Kawada K, Sonoshita M, Sakashita H et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64:4010-17. (Pubitemid 38697317)
24. Monteagudo C, Martin JM, Jorda E et al. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007; 60:596-9. (Pubitemid 46975211)
25. Palmer K, Emtage PC, Strieter RM et al. Transient gene transfer of non-ELR chemokines to rodent lung induces mononuclear cell accumulation and activation. J Interferon Cytokine Res 1999; 19:1381-90. (Pubitemid 30032940)
26. Pasco S, Ramont L, Venteo L et al. In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 2004; 301:251-65.
27. Wiley R, Palmer K, Gajewska B et al. Expression of the Th1 chemokine IFN-gamma-inducible protein 10 in the airway alters mucosal allergic sensitization in mice. J Immunol 2001; 166:2750-9.
28. Henriksen PA, Hitt M, Xing Z et al. Adenoviral gene delivery of ela- fin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 2004; 172:4535-44. (Pubitemid 38375271)
29. Debret R, El Btaouri H, Duca L et al. Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Lett 2003; 546:195-202. (Pubitemid 36782410)
30. Debret R, Le Naour RR, Sallenave JM et al. Elastin fragments induce IL-1beta upregulation via NF-kappaB pathway in melanoma cells. J Invest Dermatol 2006; 126:1860-8. (Pubitemid 44086521)
31. Feldman ED, Weinreich DM, Carroll NM et al. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 2006; 13:125-33. (Pubitemid 43117654)
32. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87:3877-82. (Pubitemid 26129617)
33. Romagnani P, Maggi L, Mazzinghi B et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005; 116:1372-9. (Pubitemid 41740951)
34. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174:164-73. (Pubitemid 40007402)
35. Kalaaji AN, Lu J, Markovic SN et al. Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine 2010; 49:287-93.
36. Gould Rothberg BE, Rimm DL. Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010; 130:1971-87.
37. Fleischer J, Grage-Griebenow E, Kasper B et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169:770-7. (Pubitemid 34753432)
38. Mocellin S, Pasquali S, Rossi CR et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493-501.
39. Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Ann NY Acad Sci 2009; 1182:47-57.
40. Eggermont AM, Testori A, Marsden J et al. Utility of adjuvant systemic therapy in melanoma. Ann Oncol 2009; 20 (Suppl. 6):vi30-4.
41. Yurkovetsky ZR, Kirkwood JM, Edington HD et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon- alpha2b. Clin Cancer Res 2007; 13:2422-8. (Pubitemid 46698593)
42. Mohty AM, Grob JJ, Mohty M et al. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 2010; 215:113-23.
43. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71. (Pubitemid 43736595)
44. Lugade AA, Moran JP, Gerber SA et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23. (Pubitemid 40806254)
45. Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
46. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27. (Pubitemid 44453458)
47. Gattinoni L, Powell DJ Jr, Rosenberg SA et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-93.
48. Cebon J, Gedye C, John T et al. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007; 5:994-1006. (Pubitemid 351479719)
49. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256-61. (Pubitemid 47510348)